Determine the necessary mass, volume, or concentration for preparing a solution.
Mavodelpar - ≥99% , CAS No.1604815-32-8
Disponible para pedir
GRADE & PURITY ≥99%
Storage
Store at 2-8°C,Desiccated
Shipped In
Wet ice
224,000+ productos de investigación · Triple ISO certified · COA & SDS Disponible para cada producto · Same-day shipping on in-stock items
Why this grade
≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Storage & shipping
Store at 2-8°C,Desiccated Ships Wet ice Check lot-specific COA for exact specifications.
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Literature proof
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Descripción general
Mavodelpar (REN001) is a selective PPARδ agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD).
In Vivo
Mavodelpar (10 mg/kg; i.p., once daily, from 6 to 17 weeks of age) effectively suppresses glomerular injury and renal fibrosis, and decreases levels of fibrosis-related proteins . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male and female B6129SF1-Col4a3 -/- mice Dosage: 10 mg/kg Administration: Intraperitoneal injection; 10 mg/kg, once daily, from 6 to 17 weeks of age Result: Suppressed proteinuria and blood urea nitrogen (BUN) levels. Reduced glomerular injury, renal fibrosis, phosho-Stat3 and connective tissue growth factor (CTGF) levels. Decreased the expression level of the activated fibroblast marker alpha-SMA and Collagen I and IV.
Form:Solid
Specifications
Especificaciones y pureza
≥99%
Mecanismos bioquímicos y fisiológicos
Mavodelpar (REN001) is a selective PPARδ agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD).
Condiciones de almacenamiento de almacenamiento
Store at 2-8°C, Desiccated
Enviado en
Wet ice
Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.
Tipo de acción
AGONIST
Pureza
≥99%
Nombres e identificadores
| Isómeros SMILES | CC1=C(C=CC(=C1)OC/C=C(\C2=CC=C(C=C2)C#CCN3CCOCC3)/C4=CC=C(C=C4)F)OCC(=O)[O-].[Na+] |
|---|---|
| PubChem CID | 122662515 |
| Peso molecular | 537.55 |
Documentation
📋 Safety Data Sheet (SDS)
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →✅ Certificate of Analysis (COA)
Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →🔬 Specification Sheet
Full quality attributes and acceptance criteria for this grade.
View spec sheet →Advanced Data
Certificados (CoA, COO, BSE/TSE y tabla de análisis)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Propiedades químicas y físicas
| Solubilidad | DMSO : 120 mg/mL (223.24 mM; Need ultrasonic) |
|---|
Calculadoras de soluciones
Reseñas
Reseñas de cliente
Remind me later
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
Copyright © 2023–present Aladdin Scientific Corp. All rights reserved.